Publications by authors named "M Feely"
Background: Prior work showed that patients from the CorEvitas Psoriasis Registry who had previously failed a prior biologic and then initiated ixekizumab demonstrated improvements in disease severity and patient-reported outcomes after 6 months. However, newer therapies such as interleukin-23 inhibitors (IL-23i) were not considered. Here, with more recent data including IL-23i, 6-month effectiveness of ixekizumab following a switch from any biologic was assessed as well as whether 6-month effectiveness of ixekizumab was impacted by prior biologic class.
View Article and Find Full Text PDFComparing Achievement of National Psoriasis Foundation Treatment Targets among Patients with Plaque Psoriasis Treated with Ixekizumab versus Other Biologics in Clinical and Real-World Studies.
Dermatol Ther (Heidelb)
April 2024
Article Synopsis
- The National Psoriasis Foundation suggests assessing the effectiveness of plaque psoriasis treatments at 12 weeks, aiming for minimal skin involvement with ixekizumab (IXE) compared to other biologics.
- A study evaluated four randomized clinical trials and a real-world study focused on moderate-to-severe psoriasis patients treated with IXE or various other biologics.
- Results indicated that IXE led to significantly better outcomes in achieving target and acceptable responses at 12 weeks compared to etanercept, guselkumab, and ustekinumab, as well as other approved treatments in real-world scenarios.
Rationale & Objective: Dialysis comes with a substantial treatment burden, so patients must select care plans that align with their preferences. We aimed to deepen the understanding of decisional regret with dialysis choices.
Study Design: This study had a mixed-methods explanatory sequential design.
Background: We report long-term, end-of-study program safety outcomes from 25 randomized clinical trials (RCTs) in adult patients with psoriasis (PsO), psoriatic arthritis (PsA), or axial spondyloarthritis (axSpA) [including ankylosing spondylitis (AS) and non-radiographic axial spondyloarthritis (nr-axSpA)] who received ≥ 1 dose of Ixekizumab (IXE) over 5 years (PsO) or up to 3 years (PsA, axSpA).
Methods: This integrated safety analysis consists of data from patients who received any dose of IXE, across 25 RCTs (17 PsO, 4 PsA, 4 axSpA). Rates of treatment-emergent adverse events (TEAEs), serious adverse events (SAEs) and selected adverse events (AEs) of interest were analyzed for all pooled studies by years of therapy and overall, through March 2022.